SCHEMBL5136687

SCHEMBL5136687

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(CC)Cc1ccccc1C(F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.43
TSHR P16473 3/20 0.41
ACHE P22303 1/20 0.39
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 3/20 0.38
HPGD P15428 3/20 0.38
HSD17B10 Q99714 3/20 0.38
CYP3A4 P08684 2/20 0.38
HSD11B1 P28845 2/20 0.38
HDAC1 Q13547 2/20 0.37
SLC6A2 P23975 2/20 0.37
SLC6A4 P31645 2/20 0.37
NR1H3 Q13133 1/20 0.36
CRHR1 P34998 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135263 0.93 C5AR1 (0.42) C5AR1TSHRACHEKDM4EALDH1A1
SCHEMBL5136285 0.93 C5AR1 (0.42) C5AR1TSHRACHEKDM4EALDH1A1
SCHEMBL5134835 0.92 C5AR1 (0.44) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5069970 0.89 SLC6A2 (0.41) C5AR1TSHRACHEKDM4EALDH1A1
SCHEMBL5136473 0.88 C5AR1 (0.44) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5135468 0.87 C5AR1 (0.46) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5137300 0.86 CCR4 (0.49) C5AR1TSHRACHEKDM4EALDH1A1
SCHEMBL5136609 0.86 C5AR1 (0.42) C5AR1TSHRACHEKDM4EALDH1A1
SCHEMBL650029 0.85 C5AR1 (0.40) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5135042 0.85 C5AR1 (0.44) C5AR1TSHRKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed